Premium
Monoclonal Epstein‐Barr virus‐related lymphoproliferative disorder following adult acute lymphoblastic leukaemia
Author(s) -
Foran James M.,
Slater Sarah E.,
Norton Andrew J.,
Wilkes Susanna J.,
Hart Ian J.,
Rohatiner Ama Z. S.
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01593.x
Subject(s) - medicine , methotrexate , lymphoproliferative disorders , chemotherapy , discontinuation , cyclophosphamide , antifolate , epstein–barr virus , acute lymphocytic leukemia , monoclonal , complication , immunology , maintenance therapy , lymphoma , virus , leukemia , monoclonal antibody , antimetabolite , lymphoblastic leukemia , antibody
A 31‐year‐old patient in remission of acute lymphoblastic leukaemia (ALL), receiving oral maintenance chemotherapy (6‐mercaptopurine, methotrexate (MTX), cyclophosphamide), developed a monoclonal, Epstein‐Barr virus (EBV)‐related lymphoproliferative disorder (LPD). Treatment consisted of excisional biopsy and the discontinuation of maintenance chemotherapy. To our knowledge, this is the first such report in an adult. The histological similarity to previous reports of ‘lymphomatoid granulomatosis’ following paediatric ALL suggests that they are the same disease. MTX may play a central role in the development of LPD in this setting. Although it is a rare complication of ALL, EBV‐related LPD should be considered in patients who develop lymphadenopathy.